Stock Price Movement and Market Context
On the trading day, Bharat Immunological & Biological Corporation Ltd’s share price fell by 4.39%, closing at Rs.16.76, the lowest level recorded in the past 52 weeks. This decline extended a three-day losing streak, during which the stock has shed 5.43% of its value. The stock’s performance lagged the Pharmaceuticals & Biotechnology sector, which itself declined by 2.1%, with Bharat Immunological underperforming the sector by 2.23% on the day.
The broader market environment was also challenging. The Sensex opened flat but subsequently dropped sharply by 1,026.91 points, or 1.28%, closing at 82,180.47. Despite this fall, the Sensex remains 4.84% below its 52-week high of 86,159.02. The index has been on a three-week consecutive decline, losing 4.18% in that period. Notably, the Sensex is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, indicating mixed technical signals.
Technical Indicators Highlight Weak Momentum
Bharat Immunological’s technical positioning is notably weak. The stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling sustained downward momentum. This technical weakness aligns with the stock’s recent price action and the broader negative trend observed over the past year.
For context, the stock’s 52-week high was Rs.29.61, indicating a steep decline of approximately 43.4% from that peak. Over the last 12 months, the stock has delivered a negative return of 35.99%, in stark contrast to the Sensex’s positive 6.63% return during the same period. This consistent underperformance extends over the last three years, with Bharat Immunological lagging behind the BSE500 index in each annual period.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Financial Performance and Fundamental Concerns
Bharat Immunological & Biological Corporation Ltd’s financial metrics reveal ongoing challenges. The company has not declared any results in the past six months, contributing to uncertainty around its current financial health. Over the last five years, the company’s net sales have contracted at an annualised rate of 24.67%, while operating profit has deteriorated sharply by 170.32% annually, indicating sustained pressure on profitability.
Recent reported figures for the nine months ended September 2023 show net sales at Rs.76.5 million, a decline of 87.03% compared to the previous period. Operating cash flow for the year was reported at Rs.0 million, the lowest level recorded, signalling limited internal cash generation. The company’s debt-equity ratio at half-year stood at a high 83.16%, reflecting elevated leverage levels.
Debt servicing capacity is a concern, with a Debt to EBITDA ratio of -1.00 times, indicating negative earnings before interest, taxes, depreciation, and amortisation relative to debt obligations. This metric underscores the company’s limited ability to meet debt commitments from operational earnings.
Risk and Valuation Considerations
The stock is considered risky relative to its historical valuation averages. Over the past year, profits have declined by 42.4%, compounding the negative return of 35.99% generated by the stock. This combination of falling earnings and share price depreciation has contributed to a downgrade in the company’s Mojo Grade from Sell to Strong Sell as of 9 April 2024, with a current Mojo Score of 3.0. The Market Cap Grade stands at 4, reflecting the company’s relatively modest market capitalisation within its sector.
These factors have contributed to the stock’s consistent underperformance against benchmarks and peers in the Pharmaceuticals & Biotechnology sector. The company’s financial and market metrics suggest a cautious stance given the current environment.
Holding Bharat Immunological & Biological Corporation Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sectoral and Market Influences
The Pharmaceuticals & Biotechnology sector has experienced a decline of 2.1% on the day, reflecting broader pressures within the industry. Bharat Immunological’s underperformance relative to its sector peers highlights company-specific challenges amid a generally subdued market environment.
The Sensex’s recent volatility and three-week downward trend have also contributed to a cautious market mood. While the index remains close to its 52-week high, the current technical setup suggests investors are weighing risks carefully, particularly in sectors facing earnings and leverage concerns.
Summary of Key Metrics
To summarise, Bharat Immunological & Biological Corporation Ltd’s key data points as of 20 Jan 2026 include:
- 52-week low price: Rs.16.76
- Day change: -4.39%
- Three-day cumulative return: -5.43%
- Mojo Score: 3.0 (Strong Sell)
- Mojo Grade change: Downgraded from Sell to Strong Sell on 9 Apr 2024
- Market Cap Grade: 4
- Net sales (9M Sep 2023): Rs.76.5 million, down 87.03%
- Operating cash flow (year): Rs.0 million
- Debt-equity ratio (HY): 83.16%
- Debt to EBITDA ratio: -1.00 times
- One-year stock return: -35.99%
- One-year profit decline: -42.4%
The combination of these factors has culminated in the stock reaching its lowest price point in a year, reflecting the challenges faced by the company amid a difficult sector and market backdrop.
Unlock special upgrade rates for a limited period. Start Saving Now →
